CFDE Data Portal | Search FLRT2-AS1

	Label	Description
	FLRT2-AS1 Gene (Entity type)	ENSG00000205562 - FLRT2 antisense RNA 1
	GSE226249 pirfenidone HL 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 progesterone fibroblast 1 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE144443 0 V 6 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 6 v 11 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE128730 3 V 5 NERATINIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 1 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

FLRT2-AS1

ENSG00000205562 - FLRT2 antisense RNA 1

GSE226249 pirfenidone HL 2 v 1 human up

A Gene Set from LINCS

GSE220806 progesterone fibroblast 1 v 3 human dn

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

A Gene Set from LINCS

GSE144443 0 V 6 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE158834 ADIPOR2 knockout HEK293 1 v 6 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 6 v 11 human up

A Gene Set from LINCS

GSE128730 3 V 5 NERATINIB HUMAN UP

A Gene Set from LINCS

GSE239844 crizotinib 1 v 10 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.